ACAlexia Carré

Alexia Carré

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexia Carré has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Coxsackievirus B escapes antiviral CD8 + T cells but triggers robust CD4 + memory responses

    by Orlando Burgos-Morales, Federica Vecchio, Fatoumata Samassa, Margot Petit, Zhicheng Zhou, Barbara Brandao, Alexia Carré, Annalisa Nicastri, Valeriia Dotsenko, Chloe Shepherd, et al.

    Coxsackieviruses B (CVBs) are plausible triggers of the pancreatic islet autoimmunity leading to type 1 diabetes. Islet autoantibody seroconversion correlates with persistent CVB infections in the gut and pancreas, suggesting defective antiviral control and the need to define immune mechanisms at the intestinal entry site. We investigated how CVB3 modulates antigen presentation, the viral immunopeptidome of enterocytes and antigen-presenting cells, and downstream T cell immunity. CVB3-infected enterocytes evaded immune recognition by down-regulating human leukocyte antigen (HLA) class I and viral peptide presentation, impairing CD8 + T cell responses in vitro. In CVB-seropositive individuals, circulating CVB-reactive CD8 + T cells were stalled in naïve-like and exhausted effector/memory states. In contrast, CVB3 induced HLA class II up-regulation, promoting robust CD4 + T cell activation. Circulating CVB3-reactive CD4 + T cells fully differentiated into polyfunctional T helper memory. These findings indicate that CVB3 antiviral control is predominantly CD4 + T cell mediated and provide a rationale for mucosal vaccination strategies and immune monitoring tools to follow infection or vaccination.


  • The antigenic visibility of beta cells as a driver of type 1 diabetes : insights from the HLA peptidome

    by Alexia Carré

    La visibilité antigénique de la cellule ß contribue-t-elle au diabète de type 1 ? : analyse par peptidomique HLA: Le diabète de type 1 (DT1) est une maladie auto-immune, qui résulte de la destruction des cellules bêta, productrices d'insuline, par des lymphocytes T (LT) CD8+ auto-réactifs. Ces LT CD8+ reconnaissent les complexes peptides-HLA de classe I (pHLA-I) exprimés à la surface des cellules bêta et notre laboratoire a montré que leur fréquence est similaire dans le sang de donneurs diabétiques et sains. Ces résultats suggèrent qu'un état universel d'auto-immunité « bénigne » existe, et interroge sur les mécanismes qui gouvernent le déclenchement du DT1. Ce changement d'état pourrait dépendre des cellules bêta elles-mêmes, qui deviendraient davantage visibles au système immunitaire. De plus, plusieurs autres protéines contenues dans les granules d'insuline sont sécrétées avec l'insuline elle-même, sous forme soluble ou dans des vésicules extracellulaires, exosomes, granules entiers. Ces composants peuvent être phagocytés, apprêtés et présentés par des cellules dendritiques dans les ganglions pancréatiques, et ainsi mener à l'activation des LT auto-réactifs. Mes travaux de thèse ont donc porté 1) sur l'étude de la visibilité de la cellule bêta soumise à différents stress, en caractérisant les peptides présentés à sa surface au sein des complexes pHLA-I (immunopeptidome) et en évaluant la contribution de certains acteurs moléculaires à leur formation. Plus précisément, je me suis intéressée à l'un des facteurs environnementaux suspectés de jouer un rôle dans le développement de la maladie, le Coxsackievirus B (CVB), ainsi qu'à l'effet de l'interféron-alpha, une cytokine signature observée précocement chez les individus à risque de développer le DT1 et qui est produite localement après infection. 2) J'ai également étudié l'immunopeptidome des cellules dendritiques exposées au sécrétome de cellules bêta afin de connaitre la nature des peptides présentés lors de l'activation des LTs. En infectant une lignée cellulaire bêta avec différentes souches de CVB, nous avons observé que le virus réduit la visibilité de la cellule bêta et peu de peptides viraux sont présentés. Nous avons aussi démontré que la réponse LT CD8+ à ces séquences est limitée et majoritairement naïve. A l'inverse, exposer les cellules bêta à l'interféron-alpha augmente fortement leur visibilité. La quantité de complexes pHLA présentée est plus importante que dans des cellules non stimulées, les peptides restreint aux allèles HLA-B sont enrichis et la diversité des peptides est accrue. Certains neo-épitopes ont été trouvés, résultant d'épissage alternative au niveau de l'ARN, au niveau peptidique ou de modifications post-traductionnelles. Le protéasome et l'immuno-protéasome ont été identifiés comme des acteurs clés dans la formation d'une grande partie de ces séquences. Enfin, la présentation croisée de peptides issus du sécretome de cellules bêta par des cellules dendritiques est plus limitée, suggérant que la phagocytose proximale de matériel antigénique au niveau pancréatique joue probablement un rôle majoritaire par rapport à la phagocytose distale d'antigènes secrétés. Ces résultats dressent une cartographie exhaustive des cibles antigéniques exposées par les cellules bêta pour la reconnaissance de la part des lymphocytes T auto-immuns. Ces antigènes offrent la possibilité de suivre les réponses auto-immunes et anti-CVB au cours de l'histoire naturel du DT1.

  • Open Access

    Decoding interaction-induced proteome changes in co-cultures with hybrid quantification and SILAC-directed real-time search

    by Alexia Carré, Sofía Ibáñez-Molero, Daniel S. Peeper, Maarten Altelaar, Kelly Stecker

    Intercellular communication between T cells and cancer cells plays a pivotal role in determining cancer cell survival or death. Yet, our understanding of this interaction remains incomplete. Methods to study heterotypic cell interactions are either limited to targeted studies relying on predefined set of proteins, or require cell separation, thus disrupting the native environment. Stable isotope labeling by amino acids in cell culture (SILAC) enables proteome distinction in heterologous co-cultures without the need for physical separation. But dynamic studies remain constrained by the need for numerous mass spectrometry (MS) runs, the challenges in detecting low-abundant proteins, particularly in immune cells and the limited data completeness due to the use of data-dependent MS 1 -based precursor quantification. To overcome these limitations, we evaluate the integration of SILAC with tandem mass tag (TMT) multiplexing and SILAC-directed real-time search (RTS). TMT labeling enables simultaneous analysis of multiple samples, while RTS-MS 3 acquisition using SILAC-induced mass shifts as fixed modifications triggers MS 3 scans for specific proteome populations within a mixed cell system, improving quantitative accuracy and proteome coverage for target protein populations. We benchmarked our acquisition methods using SILAC-labeled samples mixed at defined ratios and validated the approach in biologically relevant co-culture experiments. Additionally, we introduced a carrier channel to enhance detection of lower-abundant T cell proteins, while maintaining acceptable quantitative precision. Our results demonstrate that the combined SILAC-TMT-RTS strategy dramatically improves proteome depth, temporal resolution, and cell-type specificity for short-term co-culture interaction proteomics studies. In co-culture samples of T cells with non-small cell lung cancer cell lines that were either sensitive or resistant to T cell killing, our method revealed candidate mechanisms underlying their differential sensitivity. Our integrated approach combining SILAC, TMT and RTS to resolve cell-specific proteome dynamics in co-culture represents a novel and powerful advance.

  • Soluble HLA Class I Is Released From Human β-Cells Following Exposure to Interferons

    by Pouria Akhbari, Javier Perez-Hernandez, Mark A. Russell, Shalinee Dhayal, K. Afi Leslie, Stephanie L. Hunter, Kathryn Murrall, Alexia Carré, Noel G. Morgan, Roberto Mallone, et al.

    HLA class I (HLA-I) molecules present intracellular antigenic peptides to CD8+ T cells during immune surveillance. In donors with type 1 diabetes, hyperexpression of HLA-I occurs in islets with residual insulin-producing β-cells as a hallmark of the disease. HLA-I hyperexpression is frequently detected beyond the islet boundary, forming a “halo.” We hypothesized that this halo may reflect the diffusion of soluble forms of HLA-I (sHLA-I) from the islets to the surrounding pancreatic parenchyma. To verify this, we assessed the expression of total, cell surface, and sHLA-I in β-cell lines and isolated human islets after treatment with interferon-α (IFN-α) and IFN-γ. Consistent with the expression patterns of HLA-I in situ, the β-cell lines and cultured human islets dramatically upregulated total and surface HLA-I when exposed to IFNs. Concomitantly, sHLA-I release was significantly increased. HLA-I released within extracellular vesicles and cleaved forms of HLA-I did not significantly contribute to the sHLA-I pool. Rather, IFNs upregulated mRNA splice variants lacking the transmembrane domain. Our findings suggest that β-cells respond to IFNs by upregulating cell-associated and soluble forms of HLA-I. Soluble HLA-I may play a role in modulating islet inflammation during the autoimmune attack. Article Highlights: Hyperexpression of cell-associated HLA class I (HLA-I) induced by interferons is a hallmark feature of the residual insulin-containing pancreatic islets of people with type 1 diabetes. Soluble forms of HLA-I have also been described and are increased in the blood of individuals with viral infections and autoimmune disease, including type 1 diabetes. We assessed whether β-cells release soluble HLA-I (sHLA-I) in response to interferons. We confirm that human β-cells release significant levels of sHLA-I, demonstrate that this increases after interferon exposure, and define the release mechanism. We propose that sHLA-I may affect the activity of infiltrating CD8+ T cells in type 1 diabetes.


  • Open Access

    Interferon-α promotes HLA-B-restricted presentation of conventional and alternative antigens in human pancreatic β-cells

    by Alexia Carré, Fatoumata Samassa, Zhicheng Zhou, Javier Perez-Hernandez, Christiana Lekka, Anthony Manganaro, Masaya Oshima, Hanqing Liao, Robert Parker, Annalisa Nicastri, et al.

    Interferon (IFN)-α is the earliest cytokine signature observed in individuals at risk for type 1 diabetes (T1D), but the effect of IFN-α on the antigen repertoire of HLA Class I (HLA-I) in pancreatic β-cells is unknown. Here we characterize the HLA-I antigen presentation in resting and IFN-α-exposed β-cells and find that IFN-α increases HLA-I expression and expands peptide repertoire to those derived from alternative mRNA splicing, protein cis-splicing and post-translational modifications. While the resting β-cell immunopeptidome is dominated by HLA-A-restricted peptides, IFN-α largely favors HLA-B and only marginally upregulates HLA-A, translating into increased HLA-B-restricted peptide presentation and activation of HLA-B-restricted CD8+ T cells. Lastly, islets of patients with T1D show preferential HLA-B hyper-expression when compared with non-diabetic donors, and islet-infiltrating CD8+ T cells reactive to HLA-B-restricted granule peptides are found in T1D donors. Thus, the inflammatory milieu of insulitis may skew the autoimmune response toward alternative epitopes presented by HLA-B, hence recruiting T cells with a distinct repertoire that may be relevant to T1D pathogenesis.


  • Open Access

    Coxsackievirus infection induces direct pancreatic β cell killing but poor antiviral CD8 + T cell responses

    by Federica Vecchio, Alexia Carré, Daniil Korenkov, Zhicheng Zhou, Paola Apaolaza, Soile Tuomela, Orlando Burgos-Morales, Isaac Snowhite, Javier Perez-Hernandez, Barbara Brandao, et al.

    Coxsackievirus B (CVB) infection of pancreatic β cells is associated with β cell autoimmunity and type 1 diabetes. We investigated how CVB affects human β cells and anti-CVB T cell responses. β cells were efficiently infected by CVB in vitro, down-regulated human leukocyte antigen (HLA) class I, and presented few, selected HLA-bound viral peptides. Circulating CD8 + T cells from CVB–seropositive individuals recognized a fraction of these peptides; only another subfraction was targeted by effector/memory T cells that expressed exhaustion marker PD-1. T cells recognizing a CVB epitope cross-reacted with β cell antigen GAD. Infected β cells, which formed filopodia to propagate infection, were more efficiently killed by CVB than by CVB-reactive T cells. Our in vitro and ex vivo data highlight limited CD8 + T cell responses to CVB, supporting the rationale for CVB vaccination trials for type 1 diabetes prevention. CD8 + T cells recognizing structural and nonstructural CVB epitopes provide biomarkers to differentially follow response to infection and vaccination.


  • Open Access

    MARS an improved de novo peptide candidate selection method for non-canonical antigen target discovery in cancer

    by Hanqing Liao, Carolina Barra, Zhicheng Zhou, Xu Peng, Isaac Woodhouse, Arun Tailor, Robert Parker, Alexia Carré, Persephone Borrow, Michael J. Hogan, et al.

    Understanding the nature and extent of non-canonical human leukocyte antigen (HLA) presentation in tumour cells is a priority for target antigen discovery for the development of next generation immunotherapies in cancer. We here employ a de novo mass spectrometric sequencing approach with a refined, MHC-centric analysis strategy to detect non-canonical MHC-associated peptides specific to cancer without any prior knowledge of the target sequence from genomic or RNA sequencing data. Our strategy integrates MHC binding rank, Average local confidence scores, and peptide Retention time prediction for improved de novo candidate Selection; culminating in the machine learning model MARS. We benchmark our model on a large synthetic peptide library dataset and reanalysis of a published dataset of high-quality non-canonical MHC-associated peptide identifications in human cancer. We achieve almost 2-fold improvement for high quality spectral assignments in comparison to de novo sequencing alone with an estimated accuracy of above 85.7% when integrated with a stepwise peptide sequence mapping strategy. Finally, we utilize MARS to detect and validate lncRNA-derived peptides in human cervical tumour resections, demonstrating its suitability to discover novel, immunogenic, non-canonical peptide sequences in primary tumour tissue.


  • Open Access

    Interferon-α promotes neo-antigen formation and preferential HLA-B-restricted antigen presentation in pancreatic β-cells

    by Alexia Carré, Zhicheng Zhou, Javier Perez-Hernandez, Fatoumata Samassa, Christiana Lekka, Anthony Manganaro, Masaya Oshima, Hanqing Liao, Robert Parker, Annalisa Nicastri, et al.

    Interferon (IFN)-α is the earliest cytokine signature observed in individuals at risk for type 1 diabetes (T1D), but its effect on the repertoire of HLA Class I (HLA-I)-bound peptides presented by pancreatic β-cells is unknown. Using immunopeptidomics, we characterized the peptide/HLA-I presentation in in-vitro resting and IFN-α-exposed β-cells. IFN-α increased HLA-I expression and peptide presentation, including neo-sequences derived from alternative mRNA splicing, post-translational modifications - notably glutathionylation - and protein cis -splicing. This antigenic landscape relied on processing by both the constitutive and immune proteasome. The resting β-cell immunopeptidome was dominated by HLA-A-restricted ligands. However, IFN-α only marginally upregulated HLA-A and largely favored HLA-B, translating into a major increase in HLA-B-restricted peptides and into an increased activation of HLA-B-restricted vs. HLA-A-restricted CD8 + T-cells. A preferential HLA-B hyper-expression was also observed in the islets of T1D vs. non-diabetic donors, and we identified islet-infiltrating CD8 + T-cells from T1D donors reactive to HLA-B-restricted granule peptides. Thus, the inflammatory milieu of insulitis may skew the autoimmune response toward epitopes presented by HLA-B, hence recruiting a distinct T-cell repertoire that may be relevant to T1D pathogenesis.


  • Open Access

    Coxsackievirus infection induces direct pancreatic β-cell killing but poor anti-viral CD8+ T-cell responses

    by Federica Vecchio, Alexia Carré, Daniil Korenkov, Zhicheng Zhou, Paola Apaolaza, Soile Tuomela, Orlando Burgos-Morales, Isaac Snowhite, Javier Perez-Hernandez, Barbara Brandao, et al.

    Summary: Coxsackievirus B (CVB) infection of pancreatic β cells is associated with β-cell autoimmunity. We investigated how CVB impacts human β cells and anti-CVB T-cell responses. β cells were efficiently infected by CVB in vitro , downregulated HLA Class I and presented few, selected HLA-bound viral peptides. Circulating CD8 + T cells from CVB-seropositive individuals recognized only a fraction of these peptides, and only another sub-fraction was targeted by effector/memory T cells that expressed the exhaustion marker PD-1. T cells recognizing a CVB epitope cross-reacted with the β-cell antigen GAD. Infected β cells, which formed filopodia to propagate infection, were more efficiently killed by CVB than by CVB-reactive T cells. Thus, our in-vitro and ex-vivo data highlight limited T-cell responses to CVB, supporting the rationale for CVB vaccination trials for type 1 diabetes prevention. CD8 + T cells recognizing structural and non-structural CVB epitopes provide biomarkers to differentially follow response to infection and vaccination.


  • Coxsackievirus and Type 1 Diabetes: Diabetogenic Mechanisms and Implications for Prevention

    by Alexia Carré, Federica Vecchio, Malin Flodström-Tullberg, Sylvaine You, Roberto Mallone

    The evidence for an association between coxsackievirus B (CVB) infection, pancreatic islet autoimmunity, and clinical type 1 diabetes is increasing. Results from prospective cohorts and pancreas histopathology studies have provided a compelling case. However, the demonstration of a causal relationship is missing, and is likely to remain elusive until tested in humans by avoiding exposure to this candidate viral trigger. To this end, CVB vaccines have been developed and are entering clinical trials. However, the progress made in understanding the biology of the virus and in providing tools to address the long-standing question of causality contrasts with the scarcity of information about the antiviral immune responses triggered by infection. Beta-cell death may be primarily induced by CVB itself, possibly in the context of poor immune protection, or secondarily provoked by T-cell responses against CVB-infected beta cells. The possible involvement of epitope mimicry mechanisms skewing the physiological antiviral response toward autoimmunity has also been suggested. We here review the available evidence for each of these 3 non-mutually exclusive scenarios. Understanding which ones are at play is critical to maximize the odds of success of CVB vaccination, and to develop suitable tools to monitor the efficacy of immunization and its intermingling with autoimmune onset or prevention.